MAPT and Alzheimer disease: Pooling both Spanish population confirmed that MAPT H1 was significantly more common in AD compared to controls (73.5 versus 70.7% respectively; p = 1.0 × 10–5), and this association was predominantly due to the APOE ε4 non-carriers (p = 8.0 × 10–5) (Table 2).